Clinical Trial Search

Primary: Mean Diurnal IOP Change From Baseline at Month 3 — -7.9; -6.5; -6.4 millimeters of mercury (mmHg)

Primary: Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications — 18; 4 participants

Primary: Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety…

Primary: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30) — 640.3; 399.6 Units on a scale

Primary: Change From Baseline Trough in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) on Treatment Day 84 — 0.168; 0.142 Liters — p=0.137

Primary: Mortality From Liver Failure — 11 participants

Primary: Number of Participants With the Indicated Device Preference Based on the Size of the Numbers on the Dose Counter — 107; 86; 23; 34 participants — p=<0.001

Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 0.004; 0.119; 0.076; 0.171 Liters — p=<0.001

Primary: Body Weight — -0.76; -2.97; -0.05 Kg

Primary: Change in Spine Bone Density — 6.95; 3.76; 5.68 % change in LS BMD

Primary: Mean Change From Baseline in Systolic Blood Pressure — -7.31; -7.65; -6.67 mmHg — p=0.753

Primary: Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 — -10.49; -14.30 scores on a scale — p=<0.001

Primary: The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP)…

Primary: Parasitological Success (MITT) — 66; 28; 4; 43 participants — p=<0.005

Primary: Adverse Events — 0; 0; 0; 0 participants